

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa ID3959

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Several potential equality issues have been identified:

- | |
|---|
| <ul style="list-style-type: none">• EB disproportionately impacts people that have least and who may be culturally disadvantaged. Those with fewer resources struggle to access care, due to costs associated with organising travel to treatment centres or accessing the appropriate specialist healthcare.• Patients are particularly impacted by EB because of the high costs imposed by modifications to everyday life.• Equity of access to treatment and the challenges presented by travel by fragile-skinned RDEB patients to specialised medical centers should be considered, recognising the disability burden experienced by patients. |
|---|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee will consider carefully if its recommendations make access to beremagene geperpavec more difficult for certain groups.
--

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No additional stakeholders related to potential equality issues have been identified during the scoping or consultation process.

Approved by Associate Director: Emily Crowe

Date: 22/01/2025